Psoriasis patients exhibit impairment of the high potency CCR5+ T regulatory cell subset

•Psoriatic Tregs express lower CCR5 levels compared to Tregs from healthy controls•Healthy CCR5+Tregs show superior T-cell suppressive functions•Psoriatic skin Tregs express less CCR5 than DNCB-elicited Tregs in healthy skin•Psoriatic CCR5+ Tregs have less migratory potential compared to control CCR5+Tregs

CCR5 expression on CD4+CD25highFoxp3+ regulatory T cells (Tregs) has been reported to be crucial for limiting Th1 inflammation associated with autoimmunity and bacterial infections.We inquired whether abnormalities in chemokine receptors expressed on Tregs might be involved in the psoriatic pathogenesis. Indeed, the proportion of CCR5+ Treg was 58.8% in healthy individuals (n = 9), whereas only half as many CCR5+ Treg cells were found in psoriatic individuals (29.1%, n = 8, p < 0.01). The flow-enriched control CCR5+ Tregs consistently exceeded the suppressive capacity of unsorted Tregs in autologous MLR assays (n = 5, p < 0.05) showing that CCR5+ Treg subset is a high potency regulatory T cell population. Interestingly, psoriatic CCR5+ Treg cells exhibited significantly less migratory capacity toward CCR5 ligands MIP-1β and RANTES in vitro compared to CCR5+ Treg controls (n = 3, p < 0.05). Our data demonstrate that psoriatic CCR5+ Tregs cells are numerically-, functionally- and chemotactically-deficient compared to controls and may pose a triple impairment on the ability of psoriatic Tregs to restrain inflammation.